Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2 +:ERα - breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 15, 2012, Pages 5832-5837

  Liu, Jeff C ^a   Voisin, Veronique ^b   Bader, Gary D ^b   Deng, Tao ^a   Pusztai, Lajos ^c   Symmans, William Fraser ^c   Esteva, Francisco J ^c   Egan, Sean E ^b,d   Zacksenhaus, Eldad ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cancer stem cells; HER2 + breast cancer; Mouse models; Prognostic signature

Indexed keywords

CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STEM CELL; CELL ASSAY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL FRACTIONATION; CELL TRANSPLANTATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SIGNATURE; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PHASE TRANSITION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD24; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CELL DIFFERENTIATION; CELL DIVISION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; NEOADJUVANT THERAPY; NEOPLASTIC STEM CELLS; PROGNOSIS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

MOUSE MAMMARY TUMOR VIRUS;

EID: 84859567448     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1201105109     Document Type: Article

References (29)

1. Slamon DJ, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792. (Pubitemid 32222155)
2. Abramson V, Arteaga CL (2011) New strategies in HER2-overexpressing breast cancer: Many combinations of targeted drugs available. Clin Cancer Res 17:952-958.
3. Dean-Colomb W, Esteva FJ (2008) Her2-positive breast cancer: Herceptin and beyond. Eur J Cancer 44:2806-2812.
4. Gianni L, et al.; Herceptin Adjuvant (HERA) Trial Study Team (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244.
5. Martín M, et al. (2009) Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: Review and expert recommendations. Oncologist 14:1-11.
6. O'Brien CA, Kreso A, Dick JE (2009) Cancer stem cells in solid tumors: An overview. Semin Radiat Oncol 19:71-77.
7. Cicalese A, et al. (2009) The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138:1083-1095.
8. Korkaya H, Paulson A, Iovino F, Wicha MS (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27:6120-6130.
9. Desmedt C, et al. (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165.
10. Paik S, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826. (Pubitemid 40051905)
11. Liu R, et al. (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356:217-226. (Pubitemid 46143225)
12. Finak G, et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14:518-527. (Pubitemid 351655218)
13. Guy CT, et al. (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578-10582.
14. Liu JC, Deng T, Lehal RS, Kim J, Zacksenhaus E (2007) Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. Cancer Res 67:8671-8681. (Pubitemid 47437442)
15. Vaillant F, et al. (2008) The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res 68:7711-7717.
16. Reedijk M, et al. (2005) High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65:8530-8537. (Pubitemid 41330622)
17. Osipo C, et al. (2008) ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 27:5019-5032.
18. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115.
19. Kmieciak M, Knutson KL, Dumur CI, Manjili MH (2007) HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol 37:675-685. (Pubitemid 46916934)
20. Notta F, et al. (2011) Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469:362-367.
21. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550. (Pubitemid 41528093)
22. Merico D, Isserlin R, Stueker O, Emili A, Bader GD (2010) Enrichment map: A network-based method for gene-set enrichment visualization and interpretation. PLoS ONE 5:e13984.
23. Staaf J, et al. (2010) Identification of subtypes in human epidermal growth factor receptor 2 - positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 28:1813-1820.
24. Shirley SH, et al. (2009) Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res 69:3405-3414.
25. Whitfield ML, George LK, Grant GD, Perou CM (2006) Common markers of proliferation. Nat Rev Cancer 6:99-106. (Pubitemid 43361542)
26. Glück S, et al. (2011) TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ±trastuzumab. Breast Cancer Res Treat, 10.1007/s10549-011-1412-7.
27. Valastyan S, Weinberg RA (2011) Tumor metastasis: Molecular insights and evolving paradigms. Cell 147:275-292.
28. Geiss GK, et al. (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26:317-325. (Pubitemid 351355126)
29. Jiang Z, et al. (2010) Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest 120:3296-3309.